JNNP: Guillain-Barré syndrome anti-neurothycoside antibodies associated with SARS-CoV-2 infection.

The pandemic SARS-CoV-2 is widely distributed around the world.
coVID-19 often develop viral pneumonia and lead to life-threatening respiratory complications.
although there is little information on the neurological symptoms of COVID-19, there are reports describing Greene-Barre syndrome (GBS) as an acute symptom of SARS-CoV-2.
the authors reported that new COVID-19 cases initially showed acute GBS.
24, 2020, a 72-year-old woman arrived at the hospital's emergency department with lower back pain, weakness in her lower limbs and abnormal sensations.
in the past 10 days, she has had a fever (up to a maximum temperature of 38.5 degrees C, 101.3 degrees F), accompanied by insomnia, physical decline, dry cough and sore throat for 3 days.
3/5 for both legs and feet, and 4/5 for arms and hands, with systemic reflex disorders.
results at the time of hospitalization were not abnormal, but the fibrinogen increased (634 μg/dL; normal 200-400μg/dL) and C-reactive protein test (2.94?g/dL; normal 0.1-0.75?g/dL).
routinely performed the RT-PCR of nasopharyngeal swab SARS-CoV-2 and tested positive.
neurotranscing study (day 2) showed extended long-term incubation periods, F-wave loss, and demyelinative neuropathy.
cerebrospinal fluid (CSF) test showed a slight increase in cell count (0.02 x 109 / L, normal 0-0.01x109 / L) for all monocytes), a significant increase in protein levels (198 mg/dL, normal: slt; 55 smg / dL), and normal blood sugar levels.
-PCR of SARS-CoV-2 detected negative in cerebrospinal fluid.
screening for Epstein-Barr virus, erythic campylobacter, cytocytovirus, herpes simplex virus, chickenpox shingles virus, influenzae influenzae virus, Haemophilus influenzae, HIV and culture are negative.
these findings are usually consistent with GBS.
test for the anti-neural glycoside antibody ELISA (Bühlmann GanglioCombi) tested positive for IgG, anti-GM1, anti-GD1a and anti-GD1b.
on this day, the standard intravenous immunoglobulin programme was launched.
day after he was admitted to hospital, muscle weakness rapidly developed into flabby quadriplegic palsy and facial double paraplegia.
she developed respiratory failure with neuromuscular characteristics and was admitted to the Intensive Care Unit (ICU).
was admitted to the ICU, she was also treated with hydroxychloroquine and hydrochloric acid polycycline for 15 days.
on the 25th day, her nasopharyngeal swab SARS-CoV-2 was negative for RT-PCR.
, six other cases of GBS-related SARS-CoV-2 infection have been reported so far.
so far, anti-neuro-glycoside antibody detection (anti-GM1, anti-GD1a, and anti-GD1b) for different neural glycoside lipids represents the novelty of GBS associated with SARS-CoV-2 infection.
IgG-type anti-neurothial glycoside autoantibodies were detected in half of GBS patients.
results showed that a wide range of anti-neurothroid antibody reactions were observed in GBS patients associated with the Zika virus.
anti-neuroglycoside antibodies may cause acute astrologic polyneuropathy, but may also explain other neurological symptoms, such as insomnia, because GD1a icingotides are strongly expressed in the olfactory ocyte.
new findings provide new information about GBS as an acute clinical symptom of SARS-CoV-2.
anti-neural glycoside antibody evaluation may also help to understand other, more common neurological symptoms associated with SARS-CoV-2.
Civardi C, Collini A, Geda DJ, et al Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infect Journal of Neurology, Neurosurgery and Psimsy Published Online First: 28 August 2020. doi: 10.1136/jnnp-2020-324279 Source: MedSci Originals !-- End of Content Presentation -- !-- To Determine If Login Ends.